^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Trailblaze Pharos™

Company:
Roche
Type:
CE Marked
Related tests:
Evidence Level:
Sensitive: C4 – Case Studies

[TPR-NTRK1 fusion-Pancreatic Cancer-entrectinib]

Title:
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
Excerpt:
A TPR-NTRK1 fusion (Fig 1) was detected by NGS (Trailblaze Pharos Assay, Ignyta, San Diego, CA). He began receiving entrectinib on September 20, 2016. Immediately after initiating treatment, the patient experienced clinical benefit.
DOI:
10.1200/PO.18.00039
Trial ID: